Envestnet Asset Management Inc. Sells 2,008 Shares of Krystal Biotech, Inc. $KRYS

Envestnet Asset Management Inc. trimmed its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 13.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,108 shares of the company’s stock after selling 2,008 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Krystal Biotech were worth $2,314,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of KRYS. Hantz Financial Services Inc. boosted its holdings in shares of Krystal Biotech by 8,950.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after acquiring an additional 179 shares in the last quarter. AdvisorNet Financial Inc acquired a new stake in shares of Krystal Biotech in the third quarter valued at $30,000. Salomon & Ludwin LLC bought a new position in shares of Krystal Biotech in the third quarter valued at about $33,000. First Horizon Advisors Inc. lifted its position in Krystal Biotech by 212.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after buying an additional 166 shares in the last quarter. Finally, Caldwell Trust Co bought a new stake in Krystal Biotech during the 2nd quarter worth about $34,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $276.36 on Friday. The firm’s 50 day simple moving average is $268.29 and its 200 day simple moving average is $213.42. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $298.30. The company has a market capitalization of $8.08 billion, a price-to-earnings ratio of 40.34 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The firm had revenue of $107.11 million during the quarter, compared to the consensus estimate of $105.30 million. Equities research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insiders Place Their Bets

In other news, CAO Kathryn Romano sold 12,500 shares of Krystal Biotech stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the transaction, the chief accounting officer owned 19,318 shares in the company, valued at $5,257,200.52. The trade was a 39.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Dino A. Rossi sold 18,950 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $261.41, for a total value of $4,953,719.50. Following the completion of the transaction, the director owned 78,691 shares of the company’s stock, valued at $20,570,614.31. This represents a 19.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 116,611 shares of company stock valued at $30,008,839. Insiders own 13.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Chardan Capital upped their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Jefferies Financial Group increased their price objective on Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Finally, Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $326.25.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.